HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of MICA expression on the prognosis of advanced non-small cell lung cancer and the efficacy of CIK therapy.

AbstractOBJECTIVE:
To investigate the clinical significance of the expression of MHC class I chain-related gene A (MICA) in patients with advanced non-small cell lung cancer and explore the relationship between MICA expression and the efficacy of cytokine-induced killer cell (CIK) therapy for treating advanced non-small cell lung cancer.
METHODS:
We obtained data on 222 patients with advanced non-small cell lung cancer, including data on MICA expression, age, gender, ECOG score, pathological type, stage, treatment history (including 38 patients who were given autologous CIK cell infusion), and overall survival (OS). MICA expression in lung cancer tissue was evaluated by immunohistochemical staining. Analyses of MICA expression, and CIK therapy association with survival outcomes were performed using Cox proportional models, Kaplan-Meier methods, and the log-rank test.
RESULT:
s MICA was expressed in both membrane and cytoplasm. MICA expression correlated with the stage of lung cancer, ECOG score, gender and age. Multivariate COX regression analysis showed that the expression of MICA was an independent prognostic factor of advanced non-small cell lung cancer (pā€Š=ā€Š0.002). In subgroup analysis, we divided the 222 patients into CIK and control groups. In the CIK group, the medium OS (mOS) of patients with a high expression of MICA was longer than in those with low expression of MICA (27 months vs. 13 months). In the control group, the mOS in patients with a high expression of MICA was shorter than in patients with low MICA expression (9 months vs. 18 months). COX regression analysis showed that the MICA expression affects the effect of CIK therapy (p<0.0001).
CONCLUSION:
1) The high expression of MICA is one of the indicators of a poor prognosis for advanced non-small cell lung cancer patients. 2) The high expression of MICA might be one of the predictive factors for successful CIK therapy.
AuthorsYu Chen, Gen Lin, Zeng-qing Guo, Zhi-feng Zhou, Zhi-yong He, Yun-bin Ye
JournalPloS one (PLoS One) Vol. 8 Issue 7 Pg. e69044 ( 2013) ISSN: 1932-6203 [Electronic] United States
PMID23935919 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Histocompatibility Antigens Class I
  • KLRK1 protein, human
  • MHC class I-related chain A
  • NK Cell Lectin-Like Receptor Subfamily K
Topics
  • Carcinoma, Non-Small-Cell Lung (immunology, metabolism, pathology, therapy)
  • Cell Count
  • Cytokine-Induced Killer Cells (immunology)
  • Female
  • Flow Cytometry
  • Histocompatibility Antigens Class I (metabolism)
  • Humans
  • Immunohistochemistry
  • Immunotherapy
  • Kaplan-Meier Estimate
  • Lung Neoplasms (immunology, metabolism, pathology, therapy)
  • Male
  • Middle Aged
  • Multivariate Analysis
  • NK Cell Lectin-Like Receptor Subfamily K (metabolism)
  • Phenotype
  • Prognosis
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: